Seattle Genetics and Millennium: The Takeda Oncology Company have begun a Phase I clinical trial to evaluate brentuximab vedotin (SGN-35) in combination with chemotherapy as a treatment for newly diagnosed systemic anaplastic large cell lymphoma.
The dose-escalation Phase I trial will evaluate the safety profile, pharmacokinetics and anti-tumour activity of brentuximab vedotin when administered sequentially or in combination with multi-agent frontline chemotherapy regimens.
The study is expected to enrol 60 patients across multiple centres in the US and Europe.
Brentuximab vedotin is an antibody-drug conjugate directed to CD30, which is highly expressed in anaplastic large cell lymphoma, and is being jointly developed by Seattle Genetics and Millennium.
Under the terms of collaboration agreement, Seattle Genetics will have rights to commercialise brentuximab vedotin in the US and Canada, while Millennium will have commercialisation rights in the rest of the world.
Anaplastic large cell lymphoma is an aggressive type of T-cell non-Hodgkin lymphoma that highly expresses CD30. Approximately 2,000 people are diagnosed with the condition in the US each year.
